Clinical Trials

61 results for Prostate Cancer


STAMPEDE: Systemic Therapy in Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy - Androgen Suppression-Based Therapy Alone or Combined With Zoledronic Acid, Docetaxel, Prednisolone, Celecoxib, Abiraterone, Enzalutamide and/or Radiotherap

  • Condition: Prostate Cancer
  • Intervention: Drug: celecoxib, Drug: docetaxel, Drug: prednisolone, Drug: ADT, Drug: zoledronic acid, Drug: abiraterone, Procedure: orchiectomy, Radiation: Radiotherapy to the prostate, Drug: enzalutamide
  • Study ID: NCT00268476
View Trial

Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

  • Condition: Prostatic Neoplasms
  • Intervention: Biological: Pembrolizumab 200 mg, Drug: Olaparib 400 mg, Drug: Docetaxel 75 mg/m^2, Drug: Prednisone 5 mg, Drug: Enzalutamide 160 mg, Other: Dexamethasone 8 mg
  • Study ID: NCT02861573
View Trial

A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.

  • Condition: Prostate Cancer
  • Intervention: Drug: Ra223, Drug: Enzalutamide
  • Study ID: NCT02194842
View Trial

Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention:
  • Study ID: NCT03176381
View Trial

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer

  • Condition: Prostate Cancer Metastatic
  • Intervention: Behavioral: High intensity aerobic and resistance training, Behavioral: Psychosocial support
  • Study ID: NCT02730338
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

  • Condition: Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Drug: Abiraterone, Drug: Bicalutamide, Drug: Degarelix, Drug: Docetaxel, Drug: Flutamide, Drug: Goserelin Acetate, Drug: Histrelin Acetate, Drug: Leuprolide Acetate, Drug: Nilutamide, Procedure: Orchiectomy, Drug: Prednisone, Other: Quality-of-Life Assessment, Radiation: Radiation Therapy, Procedure: Radical Prostatectomy, Drug: Triptorelin
  • Study ID: NCT03678025
View Trial

Cytoreductive Prostatectomy Versus Cytoreductive Prostate Irradiation as a Local Treatment Option for Metastatic Prostate Cancer: a Multicentric Feasibility Trial

  • Condition: Prostate Cancer Metastatic
  • Intervention: Procedure: radical prostatectomy, Radiation: Whole pelvis radiotherapy
  • Study ID: NCT03655886
View Trial

PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

  • Condition: ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal
  • Intervention: Drug: Carboplatin, Drug: Docetaxel, Other: Laboratory Biomarker Analysis, Drug: Rucaparib Camsylate
  • Study ID: NCT03442556
View Trial

A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

  • Condition: Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
  • Intervention: Drug: Olaparib, Drug: Abiraterone Acetate, Drug: Prednisone
  • Study ID: NCT03012321
View Trial

High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency

  • Condition: Castration-resistant Prostate Cancer, Homologous Recombination Deficiency
  • Intervention: Drug: Testosterone Enanthate
  • Study ID: NCT03522064
View Trial

Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostate Cancer
  • Intervention: Drug: Docetaxel 75 mg/m2, Drug: Docetaxel 60 mg/m2, Drug: Radium-223
  • Study ID: NCT03574571
View Trial

Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Radium-223, Drug: Docetaxel
  • Study ID: NCT03230734
View Trial

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: Olaparib, Combination Product: 177Lu-PSMA
  • Study ID: NCT03874884
View Trial

A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression
  • Intervention: Other: Laboratory Biomarker Analysis, Drug: Olaparib, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT03317392
View Trial

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

  • Condition: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer
  • Intervention: Drug: Nivolumab, Drug: Ipilimumab
  • Study ID: NCT03570619
View Trial

Ice-CAP: A Phase I Trial of Ipatasertib in Combination With Atezolizumab in Patients With Advanced Solid Tumours With PI3K Pathway Hyperactivation

  • Condition: Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
  • Intervention: Drug: ipatasertib, Drug: Atezolizumab
  • Study ID: NCT03673787
View Trial

Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression

  • Condition: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
  • Intervention: Drug: Enzalutamide, Drug: Ribociclib
  • Study ID: NCT02555189
View Trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Abemaciclib, Drug: Abiraterone Acetate, Drug: Prednisone, Drug: Placebo
  • Study ID: NCT03706365
View Trial

Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer

  • Condition: Castration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer
  • Intervention: Drug: Enzalutamide, Other: Laboratory Biomarker Analysis, Radiation: Radium Ra 223 Dichloride
  • Study ID: NCT03344211
View Trial

A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: LAE001, Drug: Placebo
  • Study ID: NCT03843918
View Trial

A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Drug: Tazemetostat, Drug: Abiraterone/prednisone, Drug: Enzalutamide
  • Study ID: NCT04179864
View Trial

Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC): Efficacy and Toxicity Evaluation

  • Condition: Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive
  • Intervention: Drug: 177Lu-PSMA
  • Study ID: NCT03454750
View Trial

Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination With Enzalutamide in Adults With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Intervention: Combination Product: KPG-121 dose escalation + Enzalutamide
  • Study ID: NCT03569280
View Trial

A Phase 2 Study of a Checkpoint Inhibitor in Men With Progressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

  • Condition: Metastatic Castration Resistant Prostate Cancer
  • Intervention: Drug: Pembrolizumab
  • Study ID: NCT04104893
View Trial

Phase II Trial of pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

  • Condition: Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
  • Intervention: Biological: pTVG-HP, Biological: pTVG-AR, Drug: Pembrolizumab, Drug: rhGM-CSF
  • Study ID: NCT04090528
View Trial

ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Condition: Metastatic Castration-Resistant Prostatic Cancer
  • Intervention: Drug: Enzalutamide Oral Capsule [Xtandi], Drug: Abiraterone Oral Tablet [Zytiga], Drug: Carboplatin, Drug: Cabazitaxel 60 mg Solution for Injection, Drug: Docetaxel Injectable Solution, Drug: Radium Chloride Ra-223
  • Study ID: NCT03903835
View Trial

An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Who Failed Either Abiraterone or Enzalutamide

  • Condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Intervention: Drug: GT0918
  • Study ID: NCT03899467
View Trial

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Intervention: Biological: nivolumab, Drug: prednisone, Drug: docetaxel
  • Study ID: NCT04100018
View Trial

A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Phase I and Phase II: LAE001/prednisone + afuresertib
  • Study ID: NCT04060394
View Trial

A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  • Condition: Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplas
  • Intervention: Biological: P-PSMA-101 CAR-T cells, Drug: Rimiducid
  • Study ID: NCT04249947
View Trial

A Phase I Study to Evaluate PSCA-Targeting Chimeric Antigen Receptor (CAR)-T Cells for Patients With Metastatic Castration Resistant Prostate Cancer

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, PSCA Positive
  • Intervention: Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Drug: Cyclophosphamide, Drug: Fludarabine, Drug: Fludarabine Phosphate
  • Study ID: NCT03873805
View Trial

CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION

  • Condition: D011471, D064129, D035683, D009360, D014408
  • Intervention: Diagnostic Test: Periodic ARV7 and miRNA evaluation
  • Study ID: NCT04188275
View Trial

A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: Rucaparib, Drug: Copanlisib
  • Study ID: NCT04253262
View Trial

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

  • Condition: Metastatic Castrate Resistant Prostate Cancer
  • Intervention: Drug: Docetaxel, Radiation: Radium 223
  • Study ID: NCT03737370
View Trial

18F-Fluciclovine PET CT as an Indicator of Therapeutic Response in Metastatic Prostate Carcinoma (M1PCa)

  • Condition: Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
  • Intervention: Procedure: Computed Tomography, Drug: Fluciclovine F18, Procedure: Positron Emission Tomography
  • Study ID: NCT04134208
View Trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Intervention: Drug: REGN5678, Drug: Cemiplimab
  • Study ID: NCT03972657
View Trial

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Re

  • Condition: Metastatic Castrate Sensitive Prostate Cancer
  • Study ID: NCT04497844
View Trial

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination With Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects With Metastatic Castration-Resistant Prostate Cancer

  • Condition: Metastatic Prostate Cancer, Prostate Adenocarcinoma
  • Study ID: NCT04446117
View Trial

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTE

  • Condition: Hormone-Sensitive Prostate Cancer
  • Study ID: NCT04493853
View Trial

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

  • Condition: Prostate Cancer
  • Intervention: Drug: AZD1775, Drug: Savolitinib, Drug: Darolutamide
  • Study ID: NCT03385655
View Trial

A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy

  • Condition: Prostate Cancer
  • Intervention: Drug: IMMU-132
  • Study ID: NCT03725761
View Trial

Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

  • Condition: Prostate Cancer
  • Study ID: NCT04506567
View Trial

ENZA-p: A Randomised Phase II Trial Using PSMA as a Therapeutic Agent and Prognostic Indicator in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04419402
View Trial

Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients With Metastatic Castration Resistant Prostate Cancer Treated With Abiraterone Acetate: A Pilot Study

  • Condition: Metastatic Castration-resistant Prostate Cancer
  • Study ID: NCT04158245
View Trial

A Phase 3, Open-Label, Randomized Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

  • Condition: Metastatic Castration-Resistant Prostate Cancer
  • Study ID: NCT04647526
View Trial

A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN424 in Patients With Advanced Prostate Cancer Refractory to Androgen Therapy

  • Condition: Advanced Prostate Cancer
  • Intervention: Biological: HPN424
  • Study ID: NCT03577028
View Trial

PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naïve Men With Progressive Metastatic Castrate Resistant Prostate Cancer

  • Condition: Prostatic Neoplasms
  • Study ID: NCT04689828
View Trial

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

  • Condition: Metastatic Hormone Naive Prostate Cancer
  • Study ID: NCT04343885
View Trial

A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men With Prostate Cancer (VANDAAM Study)

  • Condition: Prostate Cancer
  • Intervention: Other: Decipher® Testing
  • Study ID: NCT02723734
View Trial
email news signup